Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Michael J. Pishvaian, Amer H. Zureikat, Charles D. Lopez, Kenneth Meredith, Emmanuel E. Zervos, Hassan Hatoum, Ki Y. Chung, Daniel James Berg, Antonio Ucar, Ripal T Gandhi, Reza Nazemzadeh, Nainesh Parikh, Paula M. Novelli, Brian Kouri, Christopher Laing, Brian A. Boone, Thor Johnson, Susan Elaine Bates, Ramtin Agah, Karyn A. Goodman
Publikováno v:
Journal of Clinical Oncology. 41:TPS773-TPS773
TPS773 Background: Prognosis for locally advanced pancreatic cancer (LAPC) remains dismal even with advances in cancer therapy. Beyond systemic therapies, local disease control is important in these patients. Local double balloon mediated delivery of
Autor:
Karyn A. Goodman, Michael J. Pishvaian, Charles D. Lopez, Kenneth Meredith, Emmanuel E. Zervos, Hassan Hatoum, Ki Y. Chung, Alex Tsobanoudis, Daniel James Berg, Antonio Ucar, Reza Nazemzadeh, Thor Johnson, Nainesh Parikh, Brian Kouri, Christopher Laing, Brian A. Boone, Imtiaz Qureshi, Ramtin Agah, Amer H. Zureikat
Publikováno v:
Journal of Clinical Oncology. 41:713-713
713 Background: Locally advanced pancreatic cancer (LAPC) remains one of the deadliest cancers. Radiation is listed as a first line therapy option in treatment guidelines and remains a common treatment for this patient population primarily for local
Autor:
Herbert J. Zeh, Jian Han, Aatur D. Singhi, Sagar N Sharma, Amer H. Zureikat, Pranav Murthy, Wenjing Pan, Nathan Bahary, Daniel Weber, Tullia C. Bruno, Miranda Byrne-Steele, Michael T. Lotze
Publikováno v:
Journal of Clinical Oncology. 39:e16001-e16001
e16001 Background: Autophagy is a cell survival mechanism that is upregulated in pancreatic ductal adenocarcinoma (PDAC). PDAC autophagy results in an altered metabolic phenotype that promotes tumor progression, chemotherapeutic resistance, and immun
Autor:
Nathan Bahary, Alessandro Paniccia, Samer AlMasri, Kenneth K. Lee, Mazen S. Zenati, Pranav Murthy, Annissa Desilva, Michael T. Lotze, Aatur D. Singhi, Richard L. Simmons, Amer H. Zureikat
Publikováno v:
Journal of Clinical Oncology. 39:4126-4126
4126 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by chronic inflammation and a tolerogenic immune response. Neutropenia is a common side effect of cytotoxic chemotherapy, managed with administration of r
Autor:
Shahriar Sharif, Antonio Ucar, Ramtin Agah, Reza Nazemzadeh, Charles Charles Li, Ki Y. Chung, Pashtoon Murtaza Kasi, Wesley B. Jones, Hassan Hatoum, Jochen Decaestecker, Thierry Delaunoit, Paula M. Novelli, Charles D. Lopez, Kenneth L Meredith, Michael J. Pishvaian, Emmanuel E. Zervos, Amer H. Zureikat, Adel Kardosh, Erik Vandestraeten, Ripal T. Gandhi
Publikováno v:
Journal of Clinical Oncology. 39:381-381
381 Background: There is no established treatment for locally advanced pancreatic cancer (LAPC), but by utilizing the regimens approved for metastatic pancreatic cancer, hope remains for rendering tumors resectable with chemotherapy. In this context,
Autor:
Adel Kardosh, Antonio Ucar, Ki Y. Chung, Ripal T. Gandhi, Aron Michael Devane, Charles D. Lopez, Thierry Delaunoit, Hassan Hatoum, Michael J. Pishvaian, Shahriar Sharif, Jochen Decaestecker, Erik Vandestraeten, Emmanuel E. Zervos, Charles Charles Li, Ramtin Agah, Reza Nazemzadeh, Amer H. Zureikat, Pashtoon Murtaza Kasi, Paula M. Novelli, Kenneth L Meredith
Publikováno v:
Journal of Clinical Oncology. 39:399-399
399 Background: For patients with pancreatic cancer, tumor growth causing obstruction of the bile duct is a common, yet troubling occurrence, leading to potential serious complications including severe infections. A common technique to correct such a
Autor:
Herbert J. Zeh, Amer H. Zureikat, Heather L. Jones, Lekshmi Ramalingam, Sara Alhelo, James F. Pingpank, Steven A. Ahrendt, Matthew P. Holtzman, David L. Bartlett, Carissa A. Low, Haroon A. Choudry, Dana H. Bovbjerg
Publikováno v:
Journal of Clinical Oncology. 34:1217-1222
Purpose The current study examined prospective relationships between preoperative depressive symptoms and short-term (30-day morbidity and readmission) and long-term (overall survival) outcomes after hyperthermic intraperitoneal chemotherapy with cyt
Autor:
Dwight E. Heron, Amer H. Zureikat, Joshua L. Rodríguez-López, Steven A. Burton, Adam C. Olson, Nathan Bahary, Ankur K. Patel
Publikováno v:
Journal of Clinical Oncology. 38:755-755
755 Background: There is no consensus on treatment volumes for stereotactic body radiation (SBRT) in patients with pancreatic cancer (PCa). Herein, we report patterns of failure following adjuvant SBRT for close/positive margins in patients with panc
Autor:
Naomi Fei, Aatur D. Singhi, Pavan Rao, M.E. Hogg, Sijin Wen, Nathan Bahary, Rajesh Ramanathan, Brian A. Boone, Amer H. Zureikat, Herbert J. Zeh, Michael T. Lotze
Publikováno v:
Journal of Clinical Oncology. 38:761-761
761 Background: SMAD4, a tumor suppressor gene, is inactivated or deleted in 60-90% of pancreatic adenocarcinomas (PDA). Loss of SMAD4 allows tumor progression by limiting cell cycle arrest and apoptosis and increasing metastases. SMAD4 deficient PDA
Autor:
Kenneth K. Lee, Adam C. Olson, Jacob C. Hodges, Aatur D. Singhi, Steven A. Burton, Amer H. Zureikat, Asmita Chopra, Herbert J. Zeh, Nathan Bahary, M.E. Hogg, Michael T. Lotze, Brian A. Boone
Publikováno v:
Journal of Clinical Oncology. 38:727-727
727 Background: Neoadjuvant therapy is increasingly used for pancreatic cancer (PDA). The comparative efficacy of neoadjuvant chemotherapy (NC) versus chemoradiation (NCRT) remains uncertain. We aimed to compare NC and NCRT on survival outcomes and p